Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker IRD
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | George Magrath Chief Executive Officer, Director | IRD Opus Genetics, Inc. | Sale | 28,258 | $3.90 | $110.2K Sale | Form 4 ↗ |
| Oct 23, 2026 | Joseph K. Schachle Chief Operating Officer | IRD Opus Genetics, Inc. | Sale | 4,767 | $3.57 | $17.0K Sale | Form 4 ↗ |
| Oct 23, 2026 | Benjamin R. Yerxa President, Director | IRD Opus Genetics, Inc. | Sale | 25,520 | $3.53 | $90.1K Sale | Form 4 ↗ |
| Oct 23, 2026 | Benjamin R. Yerxa President, Director | IRD Opus Genetics, Inc. | Sale | 7,669 | $3.55 | $27.2K Sale | Form 4 ↗ |
| Oct 23, 2026 | Robert E. Gagnon Chief Financial Officer | IRD Opus Genetics, Inc. | Sale | 14,000 | $3.55 | $49.6K Sale | Form 4 ↗ |
| Oct 23, 2026 | George Magrath Chief Executive Officer, Director | IRD Opus Genetics, Inc. | Sale | 9,591 | $3.59 | $34.4K Sale | Form 4 ↗ |
| Sep 3, 2026 | Robert E. Gagnon Chief Financial Officer | IRD Opus Genetics, Inc. | Sale | 28,000 | $4.54 | $127.1K Sale | Form 4 ↗ |
| Jul 23, 2026 | Benjamin R. Yerxa President, Director | IRD Opus Genetics, Inc. | Sale | 7,429 | $2.97 | $22.1K Sale | Form 4 ↗ |
| Jul 23, 2026 | Joseph K. Schachle Chief Operating Officer | IRD Opus Genetics, Inc. | Sale | 4,644 | $2.94 | $13.7K Sale | Form 4 ↗ |
| Jul 23, 2026 | George Magrath Chief Executive Officer, Director | IRD Opus Genetics, Inc. | Sale | 9,475 | $2.95 | $28.0K Sale | Form 4 ↗ |
| Jul 23, 2026 | Robert E. Gagnon Chief Financial Officer | IRD Opus Genetics, Inc. | Sale | 7,783 | $2.95 | $23.0K Sale | Form 4 ↗ |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund Director | IRD Opus Genetics, Inc. | Sale | 1.70M | $4.35 | $7.4M Sale | Form 4 ↗ |
| Apr 23, 2026 | Benjamin R. Yerxa President, Director | IRD Opus Genetics, Inc. | Sale | 7,470 | $5.24 | $39.1K Sale | Form 4 ↗ |
| Apr 23, 2026 | Joseph K. Schachle Chief Operating Officer | IRD Opus Genetics, Inc. | Sale | 4,697 | $5.22 | $24.5K Sale | Form 4 ↗ |
| Apr 23, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | IRD Opus Genetics, Inc. | Sale | 1,641 | $5.20 | $8,533 Sale | Form 4 ↗ |
| Apr 23, 2026 | George Magrath Chief Executive Officer, Director | IRD Opus Genetics, Inc. | Sale | 9,511 | $5.22 | $49.6K Sale | Form 4 ↗ |
| Apr 23, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | IRD Opus Genetics, Inc. | Sale | 7,542 | $5.19 | $39.1K Sale | Form 4 ↗ |
| Apr 23, 2026 | Robert E. Gagnon Chief Financial Officer | IRD Opus Genetics, Inc. | Sale | 7,842 | $5.18 | $40.6K Sale | Form 4 ↗ |
| Mar 16, 2026 | Joseph K. Schachle Chief Operating Officer | IRD Opus Genetics, Inc. | Sale | 3,719 | $5.25 | $19.5K Sale | Form 4 ↗ |
| Mar 16, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | IRD Opus Genetics, Inc. | Sale | 2,816 | $5.25 | $14.8K Sale | Form 4 ↗ |
| Mar 16, 2026 | George Magrath Chief Executive Officer, Director | IRD Opus Genetics, Inc. | Sale | 24,438 | $5.21 | $127.3K Sale | Form 4 ↗ |
| Mar 16, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | IRD Opus Genetics, Inc. | Sale | 3,719 | $5.12 | $19.0K Sale | Form 4 ↗ |
| Dec 29, 2025 | Cam Gallagher Director | IRD Opus Genetics, Inc. | Buy | 83,000 | $1.97 | $163.5K Buy | Form 4 ↗ |
| Dec 29, 2025 | Cam Gallagher Director | IRD Opus Genetics, Inc. | Buy | 81,000 | $1.98 | $160.4K Buy | Form 4 ↗ |
| Dec 9, 2025 | Foundation Fighting Blindness Retinal Degeneration Fund Director | IRD Opus Genetics, Inc. | Sale | 4.00M | $2.15 | $8.6M Sale | Form 4 ↗ |
| Dec 26, 2024 | George Magrath Chief Executive Officer | IRD Opus Genetics, Inc. | Buy | 100,000 | $0.98 | $98.0K Buy | Form 4 ↗ |
| Nov 21, 2024 | Benjamin R. Yerxa President, Director | IRD Opus Genetics, Inc. | Buy | 10,000 | $0.98 | $9,800 Buy | Form 4 ↗ |
| Nov 18, 2024 | George Magrath Chief Executive Officer | IRD Opus Genetics, Inc. | Buy | 9,706 | $1.02 | $9,900 Buy | Form 4 ↗ |
| Nov 15, 2024 | George Magrath Chief Executive Officer | IRD Opus Genetics, Inc. | Buy | 90,294 | $1.01 | $91.2K Buy | Form 4 ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances